Seaport Therapeutics, Inc. (SPTX) company profile
SPTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 2, 2026
$18.17−0.95 (-4.97%)
Close on Nov 17, 2026Market cap $972.65MP/E –Yield –
About Seaport Therapeutics
Pharmaceutical Preparations, SIC 2834
Seaport Therapeutics, Inc. is listed on Nasdaq under the ticker SPTX, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- Seaport Therapeutics, Inc.
- Headquarters
- Boston, MA
- Address
- 6 Tide Street, Suite 400 02110
- Phone
- (617) 807-4062
- Website
- seaporttx.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- SPTX
- Exchange
- Nasdaq
- IPO date
- May 1, 2026
- Shares outstanding
- 54M, Jul 27, 2026
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 2042347
- CUSIP
- 81221K108
- ISIN
- US81221K1088
- FIGI
- BBG01MBY86J1
- Share class FIGI
- BBG01MBY86L8
- EIN
- 99-2235719
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Daphne Zohar | Chief Executive Officer, Director | 1,094,001 |
| Lana Gladstein | General Counsel | 33,515 |
| Michael Cunyuan Chen | Chief Scientific Officer | 3,351 |
| Lauren White | Chief Financial Officer | 6,702 |
| Antony Loebel | Chief Medical Officer | 20,109 |
| Denice Torres | Director | 18,406 |
| Robert J. Hombach | Director | 13,000 |
| General Atlantic (SP), L.P. | Director | – |
| Gap Coinvestments Iii, Llc | Director | – |
| General Atlantic, L.P. | Director | – |
| GAP Coinvestments CDA, L.P. | Director | – |
| Gap Coinvestments Iv, Llc | Director | – |
| (Bermuda) L.P. GAP | Director | – |
| General Atlantic Genpar (Bermuda), L.P. | Director | – |
| General Atlantic Genpar, L.P. | Director | – |
| GAP Coinvestments V, LLC | Director | – |
| General Atlantic (SPV) GP, LLC | Director | 6,101,582 |
| Atlantic GenPar (Lux) SCSp General | Director | 6,101,582 |
| General Atlantic Partners (Lux), SCSp | Director | – |
| General Atlantic Partners 100, L.P. | Director | – |
| Atlantic (Lux) S.a r.l. General | Director | – |
| James Healy | Director | 1,927,159 |
| Sharon Mates | Director | – |
| Steven M. Paul | Director | 863,031 |
| David E. Wheadon | Director | – |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- May 1, 2026
- Offer price
- $18.00
- Securities offered
- 14,160,000
- Gross proceeds
- $254.88M
- Exchange
- Nasdaq
- First trading day
- May 1, 2026
- First-day close
- $19.84+10.2%
- Lock-up ends (est.)
- Oct 28, 2026
“The initial public offering price is $18.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 1, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Apr 28, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?